Skip to main content
TipRanks
Go Ultimate75% OFF

Aspire Biopharma Holdings (ASBP) Stock Statistics & Valuation Metrics

194 Followers

Total Valuation

Aspire Biopharma Holdings has a market cap or net worth of $11.64M. The enterprise value is -$4.62T.

Market Cap
$11.64M
Enterprise Value
-$4.62T

Share Statistics

Aspire Biopharma Holdings has 1,402,557 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
1,402,557
Owned by Insiders
―
Owned by Institutions
4.39%

Financial Efficiency

Aspire Biopharma Holdings’s return on equity (ROE) is 3.84 and return on invested capital (ROIC) is 395.26%.

Return on Equity (ROE)
3.84
Return on Assets (ROA)
-18.66
Return on Invested Capital (ROIC)
395.26%
Return on Capital Employed (ROCE)
3.08
Revenue Per Employee
3,101
Profits Per Employee
-12.24M
Employee Count
2
Asset Turnover
0.00
Inventory Turnover
0.02

Valuation Ratios

The current PE Ratio of Aspire Biopharma Holdings is -1.00. Aspire Biopharma Holdings’s PEG ratio is -0.01.

PE Ratio
-1.00
PS Ratio
9.44
PB Ratio
0.71
Price to FCF
-0.13
Price to Operating Cash Flow
-1.15
PEG Ratio
-0.01

Income Statement

In the last 12 months, Aspire Biopharma Holdings had revenue of 6,202 and earned -24.48M in profits. Earnings per share was -16.38.

Revenue
6,202
Gross Profit
-116
Operating Income
-19.35M
Pretax Income
-24.48M
Net Income
-24.48M
EBITDA
-11.33M
Earnings Per Share (EPS)
-16.38

Cash Flow

In the last 12 months, operating cash flow was -7.19M and capital expenditures 0, giving a free cash flow of -7.19M billion.

Operating Cash Flow
-7.19M
Free Cash Flow
-7.19M
Free Cash Flow per Share
-6.92

Dividends & Yields

Aspire Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-776.17%
Earnings Yield
-132.67%

Stock Price Statistics

Beta
1.81
52-Week Price Change
-92.42%
50-Day Moving Average
8.41
200-Day Moving Average
14.08
Relative Strength Index (RSI)
50.62
Average Volume (3m)
30.09K

Financial Position

Aspire Biopharma Holdings as a current ratio of 0.17, with Debt / Equity ratio of -21.72%

Current Ratio
0.17
Quick Ratio
0.14
Debt to Market Cap
0.01
Net Debt to EBITDA
-0.03
Interest Coverage Ratio
-2.27

Taxes

In the past 12 months, Aspire Biopharma Holdings has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Aspire Biopharma Holdings EV to EBITDA ratio is -3.42, with an EV/FCF ratio of 1.56.

EV to Sales
-115.11
EV to EBITDA
-3.42
EV to Free Cash Flow
1.56
EV to Operating Cash Flow
1.56

Balance Sheet

Aspire Biopharma Holdings has $12.17M in cash and marketable securities with $0.00 in debt, giving a net cash position of $12.17M billion.

Cash & Marketable Securities
$12.17M
Total Debt
$0.00
Net Cash
$12.17M
Net Cash Per Share
$8.67
Tangible Book Value Per Share
$11.33

Margins

Gross margin is 18.35%, with operating margin of -7259.92%, and net profit margin of -11314.24%.

Gross Margin
18.35%
Operating Margin
-7259.92%
Pretax Margin
-11314.24%
Net Profit Margin
-11314.24%
EBITDA Margin
3367.37%
EBIT Margin
-6466.27%

Analyst Forecast

The average price target for Aspire Biopharma Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
0
Revenue Growth Forecast
―
EPS Growth Forecast
94.71%